INS and obesity due to melanocortin 4 receptor deficiency: Moreover, the latest research also indicates that CBG can modulate insulin sensitivity of several tissues by affecting molecular targets, such as PPARα/γ, suggesting the potential therapeutic benefits of CBG use in such devastating diseases as obesity or metabolic syndrome (Nachnani et al., 2021; Bzdęga et al., 2023).